Jan Andersson

Jan Andersson
University of Alberta | UAlberta · Department of Oncology

PhD Radiochemistry / PET

About

50
Publications
4,151
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
832
Citations
Introduction
Over ten years experience in radiochemistry / PET. Currently working on research and development studies aimed at the commercial scale production of technetium-99m on a medical cyclotron.
Additional affiliations
November 2018 - present
Alberta Health Services
Position
  • Managing Director
November 2018 - present
University of Alberta
Position
  • Professor (Associate)
April 2012 - November 2018
University of Alberta
Position
  • Radiochemist
Education
April 2010 - March 2012
Karolinska Institutet
Field of study
  • Radiochemistry /PET
June 2005 - March 2010
Karolinska Institutet
Field of study
  • PET/Radiochemistry
August 1998 - December 2003
Uppsala University
Field of study
  • Chemical Engineering

Publications

Publications (50)
Article
Lanthanum radiometals are well positioned to serve as theranostic PET radiometals for targeted radionuclide therapy. The positron emitters ¹³²La and ¹³³La show promise to serve as unique PET imaging agents for ²²⁵Ac targeted alpha-particle therapy, the ¹³⁴Ce/¹³⁴La pair has PET imaging potential with both ²²⁵Ac and ²²⁷Th, and ¹³⁵La has potential in...
Article
Theranostic isotope pairs have gained recent clinical interest as they can be labeled to the same tracer and applied for diagnostic and therapeutic purposes. The goals of this study were to A) investigate cyclotron production of clinically relevant 133La activities using natural and isotopically enriched barium target material, B) compare fundament...
Article
Full-text available
This review outlines the accomplishments and potential developments of targeted alpha (α) particle therapy (TAT). It discusses the therapeutic advantages of the short and highly ionizing path of α-particle emissions; the ability of TAT to complement and provide superior efficacy over existing forms of radiotherapy; the physical decay properties and...
Article
Full-text available
This study reports the high-yield production of a novel 133/135La theranostic pair at a 22 MeV proton beam energy as an attractive alternative to the recently introduced 132/135La pair, demonstrating over an order of magnitude production increase of 133/135La (231 ± 8 MBq ¹³³La and 166 ± 5 MBq ¹³⁵La at End of Bombardment (EOB)) compared to 11.9 MeV...
Article
In this review, we summarize the recent development of positron emission tomography (PET) radioligands for γ-aminobutyric acid A (GABAA) receptors and their potential to measure changes in endogenous GABA levels and highlight the clinical and translational applications of GABA-sensitive PET radioligands. We review the basic physiology of the GABA s...
Article
Introduction: More than 70% of today's diagnostic radiopharmaceuticals are based on99mTc, however the conventional supply chain for obtaining99mTc is fragile. The aim of this work was to demonstrate reliable high yield production and processing of99mTc with medium-energy, high-current, cyclotrons. Methods: We used two cyclotrons (TR-24, Advanced...
Article
Hydrophobic adsorbents such as C18 and C30 were coated with PEG and subsequently used for the separation of Mo/Tc. The most effective resin for adsorbing PEG was the C18-U resin, which demonstrated a coating capacity of 97.6±2.8 mg PEG per g of resin. The ability to adsorb pertechnetate was proportional to the amount of PEG coated on the hydrophobi...
Article
Full-text available
Purpose The aim of this study was to evaluate AZD2995 side by side with AZD2184 as novel PET radioligands for imaging of amyloid-β in Alzheimer’s disease (AD). Methods In vitro binding of tritium-labelled AZD2995 and AZD2184 was studied and compared with that of the established amyloid-β PET radioligand PIB. Subsequently, a first-in-human in vivo...
Article
Introduction: The aims of the present positron emission tomography (PET) study were to set up a system for (11)C-cyanation labeling of the selective mGluR5-antagonist [(11)C]AZD9272 and to perform the first in vivo characterization of [(11)C]AZD9272 binding in cynomolgus monkeys. Methods: [(11)C]AZD9272 was labeled using palladium mediated (11)C...
Article
Full-text available
The development of positron emission tomography radioligands for the GABAA /benzodiazepine receptor complex (GABAA receptor) labeled with (11) C and (18) F is examined. The review covers labeling strategies as well as brief biological evaluations of radioligands. In addition, we assess the special considerations that must be taken during a developm...
Article
After the production of 99mTc via the 100Mo(p,2n)99mTc reaction, there is a requirement for separating 99mTc from bulk 100Mo. Although a number of separation methods have been demonstrated, the possibility of using a cartridge-based system is particularly attractive for routine use in a good manufacturing practice (GMP) regulatory environment. This...
Article
Full-text available
Unlabelled: Imaging of amyloid-β (Aβ) plaques by PET is more and more integrated into concepts for Alzheimer disease (AD) diagnosis and drug development. The objective of this study was to find novel chemical entities that can be transformed into (18)F-labeled Aβ tracers with favorable brain washout kinetics and low background signal. Methods: H...
Article
Full-text available
Background Dysfunction of the glycine transporter 1 (GlyT1) has been suggested to be involved in psychiatric disorders such as schizophrenia. GlyT1 inhibitors have therefore been considered to have antipsychotic therapeutic potential. Positron emission tomography (PET) imaging probes for GlyT1 are, consequently, expected to be useful for investigat...
Article
Full-text available
Positron-emission tomography and the radioligand [11C](R)-PK11195 have been used for the imaging of the translocator protein (TSPO) and applied to map microglia cells in the brain in neuropsychiatric disorders. [11C](R)-PK11195 binding has been quantified using reference region approaches, with the reference defined anatomically or using unsupervis...
Article
Full-text available
The serotonin 1B (5-HT(1B)) receptor has been implicated in several psychiatric disorders and is a potential pharmacological target in the treatment of depression. The aim of this study was to develop a radioligand for positron emission tomography (PET) imaging of the 5-HT(1B) receptor in the primate brain in vivo. Eight carboxamide radioligands (1...
Article
Full-text available
A novel radioligand for positron emission tomography (PET) imaging of serotonin 5-HT(1B) receptors, [(11)C]AZ10419369, has been recently described. In this study, the potential for quantitative analysis of [(11)C]AZ10419369 binding to central 5-HT(1B) receptors was evaluated in human subjects. PET measurements were performed after injection of [(11...
Article
Beta-amyloid accumulation is associated with the pathogenesis of Alzheimer's disease (AD). AZD2184, a new radioligand for high-contrast positron emission tomography (PET) imaging of Abeta-deposits, has recently been developed and characterized in vitro and in rodents ex vivo. The objective of this study was to label AZD2184 with carbon-11, to perfo...
Article
This chapter focuses on positron emission tomography (PET) imaging, the discovery of novel PET tracers, and their use in speeding drug development. In PET, a molecule is tagged with a short-lived positron-emitting isotope. Typical radioisotopes used for clinical investigations include 11C, 13N, 15O, and 18F. Using appropriate radiotracers, PET can...
Article
Full-text available
PurposeCurrent positron emission tomography (PET) radioligands for detection of Aβ amyloid in Alzheimer’s disease (AD) are not ideal for quantification. To improve the signal to noise ratio we have developed the radioligand [11C]AZD2184 and report here the first clinical evaluation. MethodsEight AD patients and four younger control subjects underw...
Article
Earlier in vivo PET experiments have demonstrated the binding of the neuroprotective alkaloid vinpocetine to the peripheral benzodiazepine receptor (PBR) or, with other terminology, the TSPO (18kDa translocator protein). With the aim of demonstrating the direct binding of vinpocetine to TSPO in vitro, two different ionidated versions of the novel T...
Article
The binding of two radiolabelled analogues (N-(5-[125I]Iodo-2-phenoxyphenyl)-N-(2,5-dimethoxybenzyl)acetamide ([125I]desfluoro-DAA1106) and N-(5-[125I]Fluoro-2-phenoxyphenyl)-N-(2-[125I]Iodo-5-methoxybenzyl)acetamide ([125I]desmethoxy-DAA1106) of the peripheral benzodiazepine receptor (PBR) (or TSPO, 18kDa translocator protein) ligand DAA1106 was e...
Article
The (14)N(rho, alpha)(11)C reaction on N(2)-O(2) or N(2)-H(2) gaseous systems as targets in proton bombardment allows for the production of [(11)C]CO(2) and [(11)C]CH(4.) We report the target production of [(11)C]CH(4) and the gas phase iodination to produce [(11)C]CH(3)I with high specific radioactivity (SA). SA was calculated for four different r...
Article
Imaging of cannabinoid subtype-1 (CB1) receptors in vivo with positron emission tomography (PET) is likely to be important for understanding their role in neuropsychiatric disorders and for drug development. Radioligands for imaging with PET are required for this purpose. We synthesized new ligands from a 3,4- diarylpyrazoline platform of which (-)...
Article
A fully automated synthesis of the important 5HT(1A) receptor radioligand, [carbonyl-(11)C]WAY-100635 (I), was developed based on the optimized one-pot "wet" synthesis procedure. A modern automated apparatus was constructed from commercially available components and operated via LabView software. In average, (906+/-525)MBq (n=94) of (I) was obtaine...
Article
The 5-HT1B receptor has been implicated in several psychiatric disorders and is a potential pharmacological target in the treatment of depression. Here we report the synthesis of a novel PET radioligand, [11C]AZ10419369 (5-methyl-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-morpholin-4-yl-phenyl)-amide), for in vivo visualizat...
Article
N-hydroxyamidines (amidoximes) may be used in prodrug technology in improving oral bioavailability of drugs containing amidino functional groups. In the body, amidoximes are reduced quickly to amidines by enzymes that are present in several organs. Ximelagatran is a benzamidoxime and ethyl ester prodrug of melagatran, which is a thrombin inhibitor....
Article
We present seven new vertebrate homologs of the prolactin-releasing hormone receptor (PRLHR) and show that these are found as two separate subtypes, PRLHR1 and PRLHR2. Analysis of a number of vertebrate sequences using phylogeny, pharmacology, and paralogon analysis indicates that the PRLHRs are likely to share a common ancestry with the neuropepti...
Article
A fully automated synthesis of the important 5HT 1A receptor radioligand, [carbonyl-11 C]WAY-100635 (I), was developed based on the optimized one-pot ''wet'' synthesis procedure. A modern automated apparatus was constructed from commercially available components and operated via LabView software. In average, (9067525) MBq (n ¼ 94) of (I) was obtain...
Article
Full-text available
The rainbow trout (Oncorhynchus mykiss) is one of the most widely used fish species in aquaculture and physiological research. In the present paper, we report the first cloning, 3D (three-dimensional) modelling, pharmacological characterization and tissue distribution of two melanocortin (MC) receptors in rainbow trout. Phylogenetic analysis indica...

Network

Cited By

Projects